Epoetin Alfa is a medicine used to treat low red blood cell counts (anemia). It helps your body make more red blood cells, which carry oxygen throughout your body. It's often used in people with kidney problems.
Every report comes from a Lived member, sent anonymously.
Have you tried Epogen (Epoetin Alfa) for Anemia?
Epoetin alfa is a prescription injection that helps the body make red blood cells. In the US it is sold as Epogen and Procrit, and Retacrit (epoetin alfa-epbx) is a biosimilar, meaning a highly similar version of the same biologic medicine, approved for the same uses. These products belong to a group called erythropoiesis-stimulating agents (ESAs). Its main use is anemia (too few red blood cells) caused by chronic kidney disease, whether or not a person is on dialysis. It is also approved for anemia caused by chemotherapy in people with cancers other than myeloid blood cancers, when at least two more months of chemotherapy are planned, and for anemia caused by zidovudine (AZT), an older HIV medicine. Some people facing planned surgery with a high chance of heavy blood loss receive it beforehand to lower the chance of needing donated blood. That use does not include heart or blood vessel surgery, or people who are willing to bank their own blood ahead of time. In every case the goal is to reduce the need for red blood cell transfusions. Epoetin alfa has not been shown to ease fatigue or improve quality of life, and it works too slowly to replace a transfusion when anemia needs correcting right away.
Healthy kidneys release a hormone called erythropoietin, which signals the bone marrow (the spongy tissue inside bones where blood is made) to produce red blood cells. Damaged kidneys make less of it, so fewer red blood cells are made. Epoetin alfa is a lab-made copy of erythropoietin with the same protein structure, and it acts on the bone marrow the same way the natural hormone does. Red blood cells carry oxygen using hemoglobin, an iron-rich protein. Hemoglobin is measured in grams per deciliter (g/dL), and that number is how the care team tracks the medicine's effect. Because the marrow needs iron to build hemoglobin, epoetin alfa works poorly when iron stores run low. Its effect is limited to red blood cell production; it does not treat the kidney disease, cancer or other condition behind the anemia.
Epoetin alfa is given as an injection under the skin or into a vein. For people on hemodialysis the vein route is recommended, so it is typically given through the dialysis line during sessions. Others receive it at a clinic or learn to inject it at home. The schedule depends on the reason for treatment: the labeled starting schedule for kidney disease is three times a week, weekly dosing is common during chemotherapy, and surgery regimens run either daily for about two weeks around the operation or weekly in the three weeks before it plus the day of surgery. The dose is based on body weight and then adjusted to hemoglobin results. Before starting, the care team checks iron levels and rules out other causes of anemia, such as vitamin deficiencies or bleeding. Most people with kidney disease need extra iron during treatment. In kidney disease, hemoglobin is checked at least weekly after starting or changing the dose, then at least monthly once it is stable, and dose increases are spaced at least four weeks apart. For home use, the vial should not be shaken, is kept in the refrigerator in its carton, and should not be used if it has been frozen. Single-dose vials are used once and any leftover is thrown away; multiple-dose vials are discarded 21 days after the first needle goes in. Needles and syringes are never reused. If a dose is missed, call the care team for instructions.
High blood pressure is the most important common side effect in people with kidney disease, and it can appear even in people who never had it before. In studies, about a quarter of dialysis patients needed new or additional blood pressure medicine. Joint pain, muscle spasms, fever, dizziness and colds or other upper respiratory infections are also common. People treated during chemotherapy or around surgery often reported nausea and vomiting, and surgery patients also reported itching, headache and injection site pain, although people given a placebo had many of the same complaints. The more serious risks come from blood clots. Get emergency care for chest pain, trouble breathing, or signs of stroke such as sudden numbness or weakness on one side of the body, trouble speaking, confusion, sudden vision loss or loss of balance. Contact the care team right away for leg pain or swelling, a cool or pale arm or leg, or a dialysis access (fistula or graft) that stops working. Epoetin alfa also raises the risk of seizures in people with kidney disease, especially in the first few months; a seizure needs medical help right away. Rarely, the body forms antibodies that block both the medicine and its own erythropoietin, causing a severe anemia called pure red cell aplasia. Unusual tiredness, lack of energy, dizziness or fainting during treatment should be reported to the care team. A serious allergic reaction (wheezing, swelling around the mouth or eyes, a widespread itchy rash) or a rash that blisters or peels means stopping the medicine and getting medical help right away.
The central safety question with epoetin alfa is how high to push hemoglobin. In large trials of people with kidney disease, aiming for hemoglobin above 11 g/dL, closer to the level of a healthy person, raised the risk of death, heart attack, stroke, heart failure and clotting of dialysis access without adding benefit. No target or dosing plan has been shown to avoid these risks, so the care team uses the lowest dose that reduces the need for transfusions and lowers or pauses the dose as hemoglobin approaches 11 g/dL for adults on dialysis, or once it goes above 10 g/dL for adults not on dialysis. A rise of more than 1 g/dL within two weeks is also a reason to cut back. Extra caution applies to people who already have heart disease or have had a stroke. In people with cancer, studies in breast, non-small cell lung, head and neck, lymphoid and cervical cancers found that ESAs shortened survival or let tumors grow or return sooner. For that reason epoetin alfa is used only for anemia caused by chemotherapy, not when the treatment is expected to cure the cancer, and it is stopped when the chemotherapy course ends. Whether to use it is a trade-off between avoiding transfusions and this risk, and is worth discussing directly with the oncologist. Around surgery it raises the chance of deep vein clots, so clot prevention (often a blood thinner) is recommended during treatment. Anyone taking epoetin alfa for any reason should tell the surgical team before an operation. It is not used when high blood pressure is uncontrolled, and blood pressure needs to be well controlled before and throughout treatment, which can mean adding medicine and following dietary limits. People who developed pure red cell aplasia after any erythropoietin medicine should not take it again or switch to another ESA. Multiple-dose vials contain benzyl alcohol, a preservative that can seriously harm newborns and infants, so they are not used in pregnancy, while breastfeeding, or in babies; benzyl alcohol free single-dose vials are used instead. After a multiple-dose vial, breastfeeding should wait at least two weeks. Data on use in pregnancy are limited, so anyone pregnant or planning pregnancy should discuss it with the prescriber. The label lists no specific drug interactions, but the care team should still know every medicine and supplement a person takes.
Epoetin alfa works gradually. Young red blood cells begin to rise within about 10 days, and hemoglobin usually climbs over 2 to 6 weeks, at a pace that varies from person to person. The aim is not a normal hemoglobin but one high enough to avoid transfusions, so the dose moves up and down with blood test results rather than staying fixed. Feeling more energetic is not a reliable sign that it is working; blood tests are the measure. If hemoglobin does not rise as expected, the team looks for a reason such as low iron, infection, inflammation or blood loss before changing course. In kidney disease, if the response is still inadequate after about 12 weeks of dose increases, higher doses are unlikely to help and may add risk. During chemotherapy, it is stopped after 8 weeks if there is no response or transfusions are still needed. How long treatment lasts depends on the reason for it. In kidney disease it is often ongoing, with regular blood pressure checks and iron monitoring. With chemotherapy it ends when the chemotherapy course ends, and before surgery it covers only the weeks around the operation.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Epogen (Epoetin Alfa), what you've noticed, or ask the community a question.